Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 1, 2007, Pages 35-39

  Pai, Manjunath P ^a   Turpin, Robin S ^b,c   Garey, Kevin W ^d  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDA; CANDIDIASIS; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TIME FACTORS;

EID: 33846025137     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00474-06     Document Type: Article

References (32)

1. Andes, D., K. Marchillo, R. Conklin, G. Krishna, F. Ezzet, A. Cacciapuoti, and D. Loebenberg. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48:137-142.
2. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:1193-1199.
3. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
4. Andes, D., and M. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
5. Antoniadou, A., H. A. Torres, R. E. Lewis, J. Thornby, G. P. Bodey, J. P. Tarrand, X. Y. Han, K. V. Rolston, A. Safdar, I. I. Raad, and D. P. Kontoyiannis. 2003. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 82:309-321.
6. Bustamante, C. I. 2005. Treatment of Candida infection: a view from the trenches! Curr. Opin. Infect. Dis. 18:490-495.
7. Canton, E., J. Peman, A. Carrillo-Munoz, A. Orero, P. Ubeda, A. Viudes, and M. Gobernado. 1999. Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. J. Clin. Microbiol. 37: 2197-2200.
8. Clancy, C. J., V. L. Yu, A. J. Morris, D. R. Snydman, and M. H. Nguyen. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177.
9. Cuenca-Estrella, M., C. B. Moore, F. Barchiesi, J. Bille, E. Chryssanthou, D. W. Denning, J. P. Donnelly, F. Dromer, B. Dupont, J. H. Rex, M. D. Richardson, B. Sancak, P. E. Verweij, and J. L. Rodriguez-Tudela. 2003. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 9:467-474.
10. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
11. Graninger, W., E. Presteril, B. Schneeweiss, B. Teleky, and A. Georgopoulos. 1993. Treatment of Candida albicans fungaemia with fluconazole. J. Infect. 26:133-146.
12. Highet, V. S., A. Forrest, C. H. Ballow, and J. J. Schentag. 1999. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J. Antimicrob. Chemother. 43(Suppl. A):55-63.
13. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
14. Kovacicova, G., Y. Krupova, M. Lovaszova, A. Roidova, J. Trupl, A. Liskova, J. Hanzen, P. Milosovic, M. Lamosova, L. Macekova, Z. Szovenyiova, A. Purgelova, T. Obertik, J. Bille, and V. Krcmery. 2000. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J. Infect. Chemother. 6:216-221.
15. Lee, S. C., C. P. Fung, J. S. Huang, C. J. Tsai, K. S. Chen, H. Y. Chen, N. Lee, L. C. See, and W. B. Shieh. 2000. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob. Agents Chemother. 44:2715-2718.
16. Louie, A., G. L. Drusano, P. Banerjee, Q. F. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
17. Louie, A., Q. F. Liu, G. L. Drusano, W. Liu, M. Mayers, E. Anaissie, and M. H. Miller. 1998. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob. Agents Chemother. 42:1512-1514.
18. Lozano-Chiu, M., S. Arikan, V. L. Paetznick, E. J. Anaissie, and J. H. Rex. 1999. Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, end point rule, species of Candida, and level of fluconazole susceptibility. J. Clin. Microbiol. 37:2755-2759.
19. Maglio, D., and D. P. Nicolau. 2004. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens. Methods Find Exp. Clin. Pharmacol. 26:781-788.
20. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empirical treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
21. Mouton, J. W. 2002. Breakpoints: current practice and future perspectives. Int. J. Antimicrob. Agents 19:323-331.
22. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Pai, M. P., and S. L. Pendland. 2003. Antifungal susceptibility testing in teaching hospitals. Ann. Pharmacother. 37:192-196.
25. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
26. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
27. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
28. Rentz, A. M., M. T. Halpern, and R. Bowden. 1998. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. 27:781-788.
29. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
30. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
31. Sobue, S., K. Tan, G. Layton, V. Leclerc, and A. Weil. 2004. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br. J. Clin. Pharmacol. 57:773-784.
32. Takakura, S., N. Fujihara, T. Saito, T. Kudo, Y. Iinuma, and S. Ichiyama. 2004. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur. J. Clin. Microbiol. Infect. Dis. 23:380-388.